Clinical Trial Update: Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

View source ↗

Summary

This clinical trial is evaluating quantitative muscle imaging as a biomarker to measure disease endpoints in myotonic dystrophy and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Myotonic Dystrophy | Status: RECRUITING